Literature DB >> 29859173

Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities.

Jacques Galipeau1, Luc Sensébé2.   

Abstract

Mesenchymal stromal cells (MSCs) have been the subject of clinical trials for more than a generation, and the outcomes of advanced clinical trials have fallen short of expectations raised by encouraging pre-clinical animal data in a wide array of disease models. In this Perspective, important biological and pharmacological disparities in pre-clinical research and human translational studies are highlighted, and analyses of clinical trial failures and recent successes provide a rational pathway to MSC regulatory approval and deployment for disorders with unmet medical needs.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Crohn’s disease; FDA; biomarkers; clinical trials; efferocytosis; graft versus host disease; immune compatibility; mesenchymal stromal cells; thawing

Mesh:

Year:  2018        PMID: 29859173      PMCID: PMC6434696          DOI: 10.1016/j.stem.2018.05.004

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  49 in total

1.  LYMPHOCYTE INTERACTION: A POTENTIAL HISTOCOMPATIBILITY TEST IN VITRO.

Authors:  F BACH; K HIRSCHHORN
Journal:  Science       Date:  1964-02-21       Impact factor: 47.728

2.  Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells.

Authors:  Luc Sensebé; Karin Tarte; Jacques Galipeau; Mauro Krampera; Ivan Martin; Donald G Phinney; Yufang Shi
Journal:  Cell Stem Cell       Date:  2012-01-06       Impact factor: 24.633

Review 3.  Mesenchymal stromal cells: sensors and switchers of inflammation.

Authors:  Maria Ester Bernardo; Willem E Fibbe
Journal:  Cell Stem Cell       Date:  2013-10-03       Impact factor: 24.633

Review 4.  Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications.

Authors:  Ying Wang; Xiaodong Chen; Wei Cao; Yufang Shi
Journal:  Nat Immunol       Date:  2014-11       Impact factor: 25.606

5.  New Governmental Regulatory System for Stem Cell-Based Therapies in Japan.

Authors:  Akinori Hara; Daisaku Sato; Yasuyuki Sahara
Journal:  Ther Innov Regul Sci       Date:  2014-11       Impact factor: 1.778

Review 6.  The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?

Authors:  Jacques Galipeau
Journal:  Cytotherapy       Date:  2013-01       Impact factor: 5.414

7.  MSC-based product characterization for clinical trials: an FDA perspective.

Authors:  Michael Mendicino; Alexander M Bailey; Keith Wonnacott; Raj K Puri; Steven R Bauer
Journal:  Cell Stem Cell       Date:  2014-02-06       Impact factor: 24.633

8.  Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.

Authors:  Julián Panés; Damián García-Olmo; Gert Van Assche; Jean Frederic Colombel; Walter Reinisch; Daniel C Baumgart; Axel Dignass; Maria Nachury; Marc Ferrante; Lili Kazemi-Shirazi; Jean C Grimaud; Fernando de la Portilla; Eran Goldin; Marie Paule Richard; Anne Leselbaum; Silvio Danese
Journal:  Lancet       Date:  2016-07-29       Impact factor: 79.321

9.  Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.

Authors:  Leigh Turner; Paul Knoepfler
Journal:  Cell Stem Cell       Date:  2016-06-30       Impact factor: 24.633

10.  Potency Analysis of Mesenchymal Stromal Cells Using a Combinatorial Assay Matrix Approach.

Authors:  Raghavan Chinnadurai; Devi Rajan; Muna Qayed; Dalia Arafat; Marco Garcia; Yifei Liu; Subra Kugathasan; Larry J Anderson; Greg Gibson; Jacques Galipeau
Journal:  Cell Rep       Date:  2018-02-27       Impact factor: 9.423

View more
  450 in total

1.  Programmable microencapsulation for enhanced mesenchymal stem cell persistence and immunomodulation.

Authors:  Angelo S Mao; Berna Özkale; Nisarg J Shah; Kyle H Vining; Tiphaine Descombes; Liyuan Zhang; Christina M Tringides; Sing-Wan Wong; Jae-Won Shin; David T Scadden; David A Weitz; David J Mooney
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-16       Impact factor: 11.205

Review 2.  There Is No "Stem Cell Mess".

Authors:  Arnold I Caplan
Journal:  Tissue Eng Part B Rev       Date:  2019-08       Impact factor: 6.389

Review 3.  The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Authors:  Alexander Rühle; Ramon Lopez Perez; Bingwen Zou; Anca-Ligia Grosu; Peter E Huber; Nils H Nicolay
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

Review 4.  Biological functions of mesenchymal stem cells and clinical implications.

Authors:  Abderrahim Naji; Masamitsu Eitoku; Benoit Favier; Frédéric Deschaseaux; Nathalie Rouas-Freiss; Narufumi Suganuma
Journal:  Cell Mol Life Sci       Date:  2019-05-04       Impact factor: 9.261

Review 5.  Frustrated differentiation of mesenchymal stem cells.

Authors:  Satoru Kidoaki
Journal:  Biophys Rev       Date:  2019-05-17

Review 6.  Next-generation stem cells - ushering in a new era of cell-based therapies.

Authors:  Erin A Kimbrel; Robert Lanza
Journal:  Nat Rev Drug Discov       Date:  2020-04-06       Impact factor: 84.694

7.  Extracellular Vesicle Therapeutics in Regenerative Medicine.

Authors:  Aya Imafuku; Sebastian Sjoqvist
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Small-sized extracellular vesicles (EVs) derived from acute myeloid leukemia bone marrow mesenchymal stem cells transfer miR-26a-5p to promote acute myeloid leukemia cell proliferation, migration, and invasion.

Authors:  Dexiang Ji; Yue He; Wei Lu; Yanyan Rong; Fei Li; Xianbao Huang; Ruibin Huang; Yanxia Jiang; Guoan Chen
Journal:  Hum Cell       Date:  2021-02-23       Impact factor: 4.174

9.  Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?

Authors:  Timothy E Krueger; Daniel L J Thorek; Alan K Meeker; John T Isaacs; W Nathaniel Brennen
Journal:  Prostate       Date:  2018-11-28       Impact factor: 4.104

10.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.

Authors:  Michael A Matthay; Carolyn S Calfee; Hanjing Zhuo; B Taylor Thompson; Jennifer G Wilson; Joseph E Levitt; Angela J Rogers; Jeffrey E Gotts; Jeanine P Wiener-Kronish; Ednan K Bajwa; Michael P Donahoe; Bryan J McVerry; Luis A Ortiz; Matthew Exline; John W Christman; Jason Abbott; Kevin L Delucchi; Lizette Caballero; Melanie McMillan; David H McKenna; Kathleen D Liu
Journal:  Lancet Respir Med       Date:  2018-11-16       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.